Functional mononucleotide repeat polymorphism in the promoter region of HGF is associated with risk and malignant aggressiveness of bladder cancer

Chiba,Syuji; Tsuchiya,Norihiko; Horikawa,Yohei; Narita,Shintaro; Inoue,Takamitsu; Akihama,Susumu; Saito,Mitsuru; Numakura,Kazuyuki; Tsuruta,Hiroshi; Huang,Mingguo; Satoh,Shigeru; Habuchi,Tomonori

doi:10.3892/ijo.2013.2221

Functional mononucleotide repeat polymorphism in the promoter region of HGF is associated with risk and malignant aggressiveness of bladder cancer

Authors:
- Syuji Chiba
- Norihiko Tsuchiya
- Yohei Horikawa
- Shintaro Narita
- Takamitsu Inoue
- Susumu Akihama
- Mitsuru Saito
- Kazuyuki Numakura
- Hiroshi Tsuruta
- Mingguo Huang
- Shigeru Satoh
- Tomonori Habuchi
View Affiliations

Affiliations: Department of Urology, Akita University Graduate School of Medicine, Akita, Japan
Published online on: December 20, 2013 https://doi.org/10.3892/ijo.2013.2221
Pages: 678-684

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Increased expression of hepatocyte growth factor (HGF) has been shown to be associated with aggressiveness in several types of cancer. Shorter variants of deoxyadenosine tract element (DATE) located in the HGF promoter region have been reported to enhance the expression of HGF. In this study, we investigated the role of HGF DATE variants in bladder cancer risk, HGF expression and clinicopathological features. The frequency of individuals with a short DATE (<28 repeats) in peripheral blood lymphocytes (PBLs) was significantly higher in bladder cancer patients compared to controls (p<0.001). Somatic mutations were observed in 37 of 70 bladder tumor (BT) tissues and the frequency of mutation to long DATE was significantly higher than that to short DATE (p=0.047). The presence of the short DATE in BT tissue was significantly associated with higher tumor grade (p=0.015). HGF mRNA levels were significantly higher in pT2 tumors than pTa or pT1 tumors (p=0.019), and in grade 3 tumors than grade 1 or 2 tumors (p=0.020). Furthermore, BT tissues with the short DATE showed significantly higher levels of HGF mRNA (p<0.001). In patients who underwent radical cystectomy, those with higher HGF expression had a significantly shorter overall survival than those with lower HGF expression (p=0.012). In conclusion, HGF may be associated with the prognosis of patients who undergo radical cystectomy, and the HGF DATE may affect the risk and aggressiveness of bladder cancer by altering HGF expression.

View Figures

View References

1.	Trusolino L and Comoglio PM: Scatter-factor and semaphorin receptors: cell signalling for invasive growth. Nat Rev Cancer. 2:289–300. 2002. View Article : Google Scholar : PubMed/NCBI
2.	Birchmeier C, Birchmeier W, Gherardi E and Vande Woude GF: Met, metastasis, motility and more. Nat Rev Mol Cell Biol. 4:915–925. 2003. View Article : Google Scholar : PubMed/NCBI
3.	Aune G, Lian AM, Tingulstad S, Torp SH, Forsmo S, Reseland JE, Stunes AK and Syversen U: Increased circulating hepatocyte growth factor (HGF): a marker of epithelial ovarian cancer and an indicator of poor prognosis. Gynecol Oncol. 121:402–406. 2011. View Article : Google Scholar : PubMed/NCBI
4.	Gohji K, Nomi M, Niitani Y, Kitazawa S, Fujii A, Katsuoka Y and Nakajima M: Independent prognostic value of serum hepatocyte growth factor in bladder cancer. J Clin Oncol. 18:2963–2971. 2000.PubMed/NCBI
5.	Saigusa S, Toiyama Y, Tanaka K, Yokoe T, Fujikawa H, Matsushita K, Okugawa Y, Inoue Y, Uchida K, Mohri Y and Kusunoki M: Inhibition of HGF/cMET expression prevents distant recurrence of rectal cancer after preoperative chemoradiotherapy. Int J Oncol. 40:583–591. 2012.PubMed/NCBI
6.	Wu CW, Li AF, Chi CW, Chung WW, Liu TY, Lui WY and P’Eng FK: Hepatocyte growth factor and Met/HGF receptors in patients with gastric adenocarcinoma. Oncol Rep. 5:817–822. 1998.PubMed/NCBI
7.	Ueki T, Fujimoto J, Suzuki T, Yamamoto H and Okamoto E: Expression of hepatocyte growth factor and its receptor c-met proto-oncogene in hepatocellular carcinoma. Hepatology. 25:862–866. 1997. View Article : Google Scholar
8.	Yamashita J, Ogawa M, Yamashita S, Nomura K, Kuramoto M, Saishoji T and Shin S: Immunoreactive hepatocyte growth factor is a strong and independent predictor of recurrence and survival in human breast cancer. Cancer Res. 54:1630–1633. 1994.PubMed/NCBI
9.	Bharti A, Ma PC, Maulik G, Singh R, Khan E, Skarin AT and Salgia R: Haptoglobin alpha-subunit and hepatocyte growth factor can potentially serve as serum tumor biomarkers in small cell lung cancer. Anticancer Res. 24:1031–1038. 2004.PubMed/NCBI
10.	Coskun U, Bukan N, Sancak B, Gunel N, Ozenirler S, Unal A and Yucel A: Serum hepatocyte growth factor and interleukin-6 levels can distinguish patients with primary or metastatic liver tumors from those with benign liver lesions. Neoplasma. 51:209–213. 2004.PubMed/NCBI
11.	Toiyama Y, Miki C, Inoue Y, Okugawa Y, Tanaka K and Kusunoki M: Serum hepatocyte growth factor as a prognostic marker for stage II or III colorectal cancer patients. Int J Cancer. 125:1657–1662. 2009. View Article : Google Scholar : PubMed/NCBI
12.	Tanimoto S, Fukumori T, El-Moula G, Shiirevnyamba A, Kinouchi S, Koizumi T, Nakanishi R, Yamamoto Y, Taue R, Yamaguchi K, Nakatsuji H, Kishimoto T, et al: Prognostic significance of serum hepatocyte growth factor in clear cell renal cell carcinoma: comparison with serum vascular endothelial growth factor. J Med Invest. 55:106–111. 2008. View Article : Google Scholar : PubMed/NCBI
13.	Chau GY, Lui WY, Chi CW, Chau YP, Li AF, Kao HL and Wu CW: Significance of serum hepatocyte growth factor levels in patients with hepatocellular carcinoma undergoing hepatic resection. Eur J Surg Oncol. 34:333–338. 2008. View Article : Google Scholar : PubMed/NCBI
14.	Ma J, DeFrances MC, Zou C, Johnson C, Ferrell R and Zarnegar R: Somatic mutation and functional polymorphism of a novel regulatory element in the HGF gene promoter causes its aberrant expression in human breast cancer. J Clin Invest. 119:478–491. 2009. View Article : Google Scholar : PubMed/NCBI
15.	Shimizu M, Mori T, Sakurai T and Shindo H: Destabilization of nucleosomes by an unusual DNA conformation adopted by poly(dA) small middle dotpoly(dT) tracts in vivo. EMBO J. 19:3358–3365. 2000. View Article : Google Scholar : PubMed/NCBI
16.	Koch KA and Thiele DJ: Functional analysis of a homopolymeric (dA-dT) element that provides nucleosomal access to yeast and mammalian transcription factors. J Biol Chem. 274:23752–23760. 1999. View Article : Google Scholar : PubMed/NCBI
17.	Fox KR: Wrapping of genomic polydA.polydT tracts around nucleosome core particles. Nucleic Acids Res. 20:1235–1242. 1992. View Article : Google Scholar : PubMed/NCBI
18.	Iyer V and Struhl K: Poly(dA:dT), a ubiquitous promoter element that stimulates transcription via its intrinsic DNA structure. EMBO J. 14:2570–2579. 1995.PubMed/NCBI
19.	Anderson JD and Widom J: Poly(dA-dT) promoter elements increase the equilibrium accessibility of nucleosomal DNA target sites. Mol Cell Biol. 21:3830–3839. 2001. View Article : Google Scholar : PubMed/NCBI
20.	Reardon BJ, Winters RS, Gordon D and Winter E: A peptide motif that recognizes A.T tracts in DNA. Proc Natl Acad Sci USA. 90:11327–11331. 1993. View Article : Google Scholar : PubMed/NCBI
21.	Graziano F, Galluccio N, Lorenzini P, Ruzzo A, Canestrari E, D’Emidio S, Catalano V, Sisti V, Ligorio C, Andreoni F, Rulli E, Di Oto E, et al: Genetic activation of the MET pathway and prognosis of patients with high-risk, radically resected gastric cancer. J Clin Oncol. 29:4789–4795. 2011. View Article : Google Scholar : PubMed/NCBI
22.	Lopez-Beltran A and Montironi R: Non-invasive urothelial neoplasms: according to the most recent WHO classification. Eur Urol. 46:170–176. 2004. View Article : Google Scholar : PubMed/NCBI
23.	Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL and Trotti A: Urinary bladder. AJCC Cancer Staging Manual. 7th edition. Springer; New York, NY: pp. 497–505. 2010